Alzheimer's Disease Clinical Trials in Los Angeles, CA

46 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Testing & Refinement of CarePair: An Assessment and Referral Platform to Support Family Caregivers of Alzheimer's Disease and Related Dementias.	N/A	University of Southern California	<1 mi
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	<1 mi
Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)	Phase 1/2	University of California, Los Angeles	<1 mi
Polyphenols and Cognitive Decline	N/A	University of California, Los Angeles	<1 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	<1 mi
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Phase 2/3	Washington University School of Medicine	<1 mi
[18F]PI-2620 Phase 3 Histopathological Study	Phase 3	Lantheus Biosciences Ltd.	<1 mi
Cardiac-Control Affecting Learning Through Mindfulness (CALM)	N/A	University of Southern California	<1 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	<1 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)	Phase 3	Bristol-Myers Squibb	<1 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant	Phase 3	Eidos Therapeutics, a BridgeBio company	<1 mi
A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers	N/A	University of California, Los Angeles	<1 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)	Phase 2	Merck Sharp & Dohme LLC	<1 mi
Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study	N/A	Cedars-Sinai Medical Center	<1 mi
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Phase 2/3	Washington University School of Medicine	<1 mi
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease	Phase 2	Novartis Pharmaceuticals	<1 mi
A Study of LY3439539 in Participants With Alzheimer's Disease	Phase 1	Eli Lilly and Company	<1 mi
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease	Phase 1/2	NKGen Biotech, Inc.	6 mi
Open-Label Extension Protocol to SNK01-AD01 Study	Phase 2	NKGen Biotech, Inc.	6 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease	Phase 3	Bristol-Myers Squibb	9 mi
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)	Phase 3	Bristol-Myers Squibb	9 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	9 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies	Phase 3	Hoffmann-La Roche	9 mi
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions	Phase 1/2	Thomas Advanced Medical LLC	9 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	14 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease	Phase 2	Celgene	14 mi
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease	Phase 2	Lighthouse Pharmaceuticals, Inc.	14 mi
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	14 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)	Phase 3	Bristol-Myers Squibb	16 mi
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)	Phase 1	Eli Lilly and Company	20 mi
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease	Phase 2	Intra-Cellular Therapies, Inc.	20 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease	Phase 3	Bristol-Myers Squibb	20 mi
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis	Phase 2	MapLight Therapeutics	20 mi
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).	Phase 3	Eli Lilly and Company	20 mi
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia	Phase 2	Intra-Cellular Therapies, Inc.	24 mi
ACP-204 in Adults With Alzheimer's Disease Psychosis	Phase 2/3	ACADIA Pharmaceuticals Inc.	24 mi
Trial-Ready Cohort-Down Syndrome (TRC-DS)	—	University of Southern California	29 mi
Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders	N/A	University of Michigan	29 mi
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)	Phase 4	Alpha Cognition, Inc	29 mi
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	30 mi
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type	Phase 2	Teikoku Pharma USA, Inc.	32 mi
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)	Phase 3	Bristol-Myers Squibb	32 mi
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease	Phase 1	Regeneration Biomedical, Inc.	35 mi
Biomarker Exploration in Aging, Cognition and Neurodegeneration	Phase 3	University of California, Irvine	36 mi
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease	Phase 1/2	AbbVie	36 mi
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)	Phase 2	Eli Lilly and Company	36 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.